Manuscript Proposals & Publications

• Efficacy of once-daily high-dose oral insulin immunotherapy in children genetically at risk for type 1 diabetes: A European randomized, placebo-controlled primary prevention trial (POInT).
  Ziegler AG, Achenbach P, Weiss A, et al. (in press). The Lancet.
• Epigenetic differences at immune and type 1 diabetes susceptibility genes in blood from young children after COVID-19 infection.
  Ott R, Singh T, et al. (2025). Journal of Autoimmunity.
• Genetics of circulating proteins in newborn babies at high risk of type 1 diabetes.
  Tutino M, Yu NY, et al. (2025). Nature Communications, 16(1), 3750.
• Blood methylome signatures in children exposed to maternal type 1 diabetes are linked to protection against islet autoimmunity.
  Ott R, Zapardiel-Gonzalo J, et al. (2025). Nature Metabolism.
• Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol.
  Hummel S, Käßl A, et al. (2025). Contemporary Clinical Trials Communications.

• Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemic.
  Zeller I, Ziegler AG, et al. (2024). Infection, 52(6), 2465–2473.
• Early-childhood body mass index and its association with the COVID-19 pandemic, containment measures and islet autoimmunity in children with increased risk for type 1 diabetes.
  Hummel S, Ziegler AG, et al. (2024). Diabetologia, 67(4), 670–678.
• Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes.
  Hendriks E, Marcovecchio L, et al. (2024). Diabetes/Metabolism Research and Reviews, 40(2), e3777.
• Vitamin D insufficiency in infants with increased risk of developing type 1 diabetes: A secondary analysis of the POInT study.
  Jacobs A, Warnants M, et al. (2024). BMJ Paediatrics Open, 8(1), e002212.

• SARS-CoV-2 infection and development of islet autoimmunity in early childhood.
  Bonifacio E, Lugar M, et al. (2023). JAMA, 330(12), 1151–1160.
• Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
  Bendor-Samuel OM, Wishlade T, Willis L, et al.; GPPAD Study Group. (2023). Archives of Disease in Childhood, 108(1), 26–30.

• The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT study.
  Houben J, Janssens M, et al. (2022). Pediatric Diabetes, 23(8), 1707–1716.
• Elevations in blood glucose before and after the appearance of islet autoantibodies in children.
  Warncke K, Weiss A, et al. (2022). Journal of Clinical Investigation, 132(20), e162123.

• Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: The GPPAD-SINT1A randomized controlled trial protocol.
  Ziegler AG, Arnolds S, et al. (2021). BMJ Open, 11(11), e052449

• Identification of infants with increased type 1 diabetes genetic risk for enrollment into primary prevention trials – GPPAD-02 study design and first results.
  Winkler C, Haupt F, et al.; GPPAD Study Group. (2019). Pediatric Diabetes, 20(6), 720–727.
• Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: The GPPAD-POInT study protocol.
  Ziegler AG, Achenbach P, et al. (2019). BMJ Open, 9(6), e028578.

• Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives.
  Ziegler AG, Danne T, Dunger DB, et al. (2016). Molecular Metabolism, 5(4), 255–262.

POInT Manuscript Proposals (GPPAD-03):

• Investigation of the relationship between HLA/ major autoimmune-variants and microbiome in the pathophysiology of Type 1 Diabetes
  H. Roach, J. Todd et al
• Neutrophil and whole blood counts in children with increased risk for type 1 diabetes
  G. Gemulla, A. Hommel, E. Bonifacio et al
• Early metabolic markers in relation to growth and development of islet autoimmunity in POInT
  H. Elding-Larsson et al
• Parental anxiety before and after their child develops islet autoantibodies
  J. Melin et al
• Analysis plan: Capacity of peripheral blood DNA methylation to predict progression from stage 1 to stage 3 type 1 diabetes in the Fr1da study
  C. Relton (University Bristol, UK), A.G. Ziegler et al
• Natural history of autoimmunity in children with increased risk of type 1 diabetes: from birth to insulin-dependency
  O. Kordonouri et al
• Tissue transglutaminase and thyroid peroxidase autoimmunity in children with an elevated genetic risk for type 1 diabetes.
  M. Sporreiter, E. Bonifacio, A.G. Ziegler
• Single cell multiome signatures to decipher the maternal T1D induced protective mechanisms against islet autoimmunity development (for POInT PBMC samples in Munich and Dresden)
  E. Bonifacio, A.G. Ziegler, F. Büttner (University of Frankfurt / DKFZ)
• Early metabolic markers and growth in relation to thyroid autoimmunity
  H. Elding-Larsson et all
• Association between vitamin D levels in children at genetic risk for type 1 diabetes and the development of beta-cell autoimmunity: a secondary analysis of the POInT study 
  An Jacobs et al 

SINT1A Manuscript Proposals (GPPAD-04):

• HbA1c levels in young children with a genetic risk for type 1 diabetes (0-5 years old)
  K. Casteels, A. Jacobs et al
• Feasibility of a fast turnaround genetic screening for type 1 diabetes risk in newborns – Recruiting children for the GPPAD primary prevention trial SINT1A
  Haupt, A. Fehn et al
• Breastfeeding behaviour and respiratory infections in SINT1A 
  S. Hummel 

POInT & SINT1A Manuscript Proposals (GPPAD-03, 04):

• Characteristics of children enrolled in GPPAD primary prevention trials POInT and SINT1A (submitted)
  S. Hummel, A. G. Ziegler et al
• Starting insulin in children transitioning to stage 3 T1D: experience from the GPPAD consortium
  Besser et al

Newborn Screening Manuscript Proposals (GPPAD-02):

• European newborn screening for an increased risk of type 1 diabetes
  C. Winkler et al